Please use this identifier to cite or link to this item: https://doi.org/10.1159/000126919
Title: Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients
Authors: Gan, R.
Lambert, C.
Lianting, J.
Chan, E.S.Y. 
Venketasubramanian, N.
Chen, C.
Chan, B.P.L.
Meyer Samama, M.
Bousser, M.G.
Keywords: Danqi Piantan Jiaonang, stroke
Safety studies
Traditional Chinese medicine
Issue Date: May-2008
Citation: Gan, R., Lambert, C., Lianting, J., Chan, E.S.Y., Venketasubramanian, N., Chen, C., Chan, B.P.L., Meyer Samama, M., Bousser, M.G. (2008-05). Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients. Cerebrovascular Diseases 25 (5) : 450-456. ScholarBank@NUS Repository. https://doi.org/10.1159/000126919
Abstract: Background and Objective: Previous studies on Danqi Piantan Jiaonang (DPJ, NeuroAid®), a traditional Chinese medicine, in stroke patients showed promising results. Our aim was to determine the safety of DPJ in normal subjects and stroke patients through a series of studies assessing its immediate and long-term effects, alone and in combination with aspirin, on hematological, hemostatic, and biochemical parameters. Methods: We conducted 3 studies from December 2004 to May 2006. Study 1 was a case series which recruited 32 healthy volunteers who were given 2 oral doses of 4 DPJ capsules (0.4 g/capsule) 6 h apart. Study 2 was a randomized controlled trial of 22 healthy volunteers who received either 1 oral dose of aspirin 300 mg alone or a combination of 1 dose of aspirin 300 mg and 2 doses of 4 DPJ capsules taken 6 h apart. For both studies 1 and 2, hemostatic parameters (prothrombin time, activated partial thromboplastin time, fibrinogen, platelet aggregation, D-dimer) were tested at baseline, and after 2 and 8 h. Study 3 was a case series which recruited 10 patients with recent ischemic stroke (within 7 days) who were given 4 DPJ capsules taken orally 3 times a day for 1 month. Blood tests for hemostatic, hematological (complete blood count), and biochemical parameters (glucose, creatinine, alanine aminotransferase, aspartate transaminase, C-reactive protein) were performed at baseline, and after 1 and 4 weeks. Results: Apart from the expected changes in platelet aggregation in subjects taking aspirin, no significant differences were detected in hemostatic parameters at baseline, and 2 and 8 h after oral intake of DPJ alone or in combination with aspirin. Likewise, no significant differences were observed in hematological, hemostatic, and biochemical parameters at baseline, and after 1 and 4 weeks of oral intake of DPJ. Conclusion: DPJ does not significantly modify hematological, hemostatic, and biochemical parameters in normal subjects and stroke patients. Copyright © 2008 S. Karger AG.
Source Title: Cerebrovascular Diseases
URI: http://scholarbank.nus.edu.sg/handle/10635/115054
ISSN: 10159770
DOI: 10.1159/000126919
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

29
checked on Jul 24, 2021

WEB OF SCIENCETM
Citations

28
checked on Jul 9, 2019

Page view(s)

88
checked on Jul 12, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.